Saad Z. Usmani, MBA, MD: Expert Perspective on the Use of Ciltacabtagene Autoleucel in Multiple Myeloma

Saad Z. Usmani, MBA, MD, of the Levine Cancer Institute, discusses new findings in patients with relapsed or refractory multiple myeloma who were given a single infusion of ciltacabtagene autoleucel and experienced responses, and what it could mean clinically going forward, especially for those receiving later lines of therapy.